Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience

Eur J Cancer. 2019 Dec;123:25-27. doi: 10.1016/j.ejca.2019.09.020. Epub 2019 Oct 23.
No abstract available

Keywords: Clinical trials; Drug development; Marketing authorisation; Regulation; Sarcoma.

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Doxorubicin / therapeutic use*
  • Drug Approval*
  • Drug Development
  • European Union
  • Humans
  • Marketing*
  • Product Recalls and Withdrawals
  • Sarcoma / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Doxorubicin
  • olaratumab